[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339256-105":59,"doc-detail-339256-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","evolution-of-diagnoses-survival-and-costs-of-oncological-medical-treatment-for-non-small-cell-lung-cancer-over-20-years-in-osona-catalonia","Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia","","Non-small-cell lung cancer (NSCLC) has undergone multiple diagnostic and therapeutic changes over the last twenty years, but real-world evidence linking evolving drug costs to patient survival remains limited. Data from the University Hospital of Vic tumor registry (2002–2021) were analyzed across 905 NSCLC patients, covering epidemiological/pathological features, oncological treatments, and survival at least 18 months after diagnosis. Pharmacological costs were matched to individualized therapies to estimate treatment cost burdens. Results show histopathology shifts, chemotherapy decline with immunotherapy rise, and advanced-stage survival gains alongside increasing costs after immunotherapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evolution-of-diagnoses-survival-and-costs-of-oncological-medical-treatment-for-non-small-cell-lung-cancer-over-20-years-in-osona-catalonia/339256/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evolution-of-diagnoses-survival-and-costs-of-oncological-medical-treatment-for-non-small-cell-lung-cancer-over-20-years-in-osona-catalonia/339256.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What data source and time span were used for the NSCLC analysis?","Question",{"text":113,"@type":114},"Patient data were collected from the University Hospital of Vic tumor registry from 2002 to 2021.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were treatment costs estimated in the study?",{"text":118,"@type":114},"Pharmacological costs were collected and aligned with the specific oncological treatments received by each patient to determine individualized treatment costs.",{"name":120,"@type":111,"acceptedAnswer":121},"What main trends were observed after immunotherapy introduction?",{"text":122,"@type":114},"In advanced stages, survival at 18 months improved, while mean treatment costs increased in the most recent years.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339256,1790197810,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Article  \nEvolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over  \n20 Years in Osona, Catalonia  \nMarta Parera Roig 1,2,3,4, *, David Compte Colomé 5, Gemma Basagaña Colomer 6, Emilia Gabriela Sardo 1,2, Mauricio Alejandro Tournour 1, Silvia Griñó Fernández 1, Arturo Ivan Ominetti 1, Emma Puigoriol Juvanteny 7,8, José Luis Molinero Polo 9, Daniel Badia Jobal 2,9 and Nadia Espejo-Herrera 2,8,9  \nCitation: Parera Roig, M.; Colomé, D.C.; Colomer, G.B.; Sardo, E.G.; Tournour, M.A.; Fernández, S.G.; Ominetti, A.I.; Juvanteny, E.P.; Polo, J.L.M.; Jobal, D.B.; et al. Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia. Curr. Oncol. 2024, 31, 2145–2157. [https://](https://)[ ](https://)[doi.org/10.3390/curroncol31040159](doi.org/10.3390/curroncol31040159)  \nReceived: 11 March 2024  \nRevised: 4 April 2024  \nAccepted: 6 April 2024  \nPublished: 9 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Oncohematology Unit, Consorci Hospitalari de Vic (University Hospital of Vic), 08500 Vic, Spain; [esardo@chv.cat](esardo@chv.cat) (E.G.S.); [matournour@chv.cat](matournour@chv.cat) (M.A.T.); [sgrino@chv.cat](sgrino@chv.cat) (S.G.F.); [aiominetti@chv.cat](aiominetti@chv.cat) (A.I.O.)  \n2 School of Medicine, University of Vic-Central University of Catalonia (UVIC-UCC), 08500 Vic, Spain; [dbadia@chv.cat](dbadia@chv.cat) (D.B.J.); [ncespejo@chv.cat](ncespejo@chv.cat) (N.E.-H.)  \n3 Doctoral College, Medicine and Biomedical Sciences, University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Spain  \n4 Mechanisms of Disease Laboratory Research Group (MoD Lab), IRIS-CC, University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Spain  \n5 Planning and Information Systems Department, Consorci Hospitalari de Vic (University Hospital of Vic), 08500 Vic, Spain; [dcompte@chv.cat](dcompte@chv.cat)  \n6 Pharmacy Department, Consorci Hospitalari de Vic (University Hospital of Vic), 08500 Vic, Spain; [gbasagana@chv.cat](gbasagana@chv.cat)  \n7 Epidemiology Department, Consorci Hospitalari de Vic (University Hospital of Vic), 08500 Vic, Spain; [epuigoriol@chv.cat](epuigoriol@chv.cat)  \n8 Multidisciplinary Inflammation Research Group (MIRG), IRIS-CC, 08500 Vic, Spain  \n9 Pathology Department, Consorci Hospitalari de Vic (University Hospital of Vic), 08500 Vic, Spain; [jlmolinero@chv.cat](jlmolinero@chv.cat)  \n* [Correspondence: mparera@chv.cat](Correspondence: mparera@chv.cat)  \nAbstract: Non-small-cell lung cancer (NSCLC) has experienced several diagnostic and therapeutic changes over the past two decades. However, there are few studies conducted with real-world data regarding the evolution of the cost of these new drugs and the corresponding changes in the survival of these patients. We collected data on patients diagnosed with NSCLC from the tumor registry of the University Hospital of Vic from 2002 to 2021 . We analyzed the epidemiological and pathological characteristics of these patients, the diverse oncological treatments administered, and the survival outcomes extending at least 18 months post-diagnosis. We also collected data on pharmacological costs, aligning them with the treatments received by each patient to determine the cost associated with individualized treatments. Our study included 905 patients diagnosed with NSCLC. We observed a dynamic shift in histopathological subtypes from squamous carcinoma in the initial years toadenocarcinoma. Regarding the treatment approach, the use of chemotherapy declined over time, replaced by immunotherapy, while molecular ther","cbCaioUyMCr28RJp","https://ap.wps.com/l/cbCaioUyMCr28RJp","pdf",1257481,13,"English","# Introduction\n# Materials and Methods\n## Study Population and Data Sources\n## Treatments and Cost Assessment\n## Survival Outcomes\n# Results\n## Patient and Tumor Characteristics\n## Treatment Patterns\n## Survival Trends and Costs\n# Discussion\n# Conclusions","[{\"question\":\"What data source and time span were used for the NSCLC analysis?\",\"answer\":\"Patient data were collected from the University Hospital of Vic tumor registry from 2002 to 2021.\"},{\"question\":\"How were treatment costs estimated in the study?\",\"answer\":\"Pharmacological costs were collected and aligned with the specific oncological treatments received by each patient to determine individualized treatment costs.\"},{\"question\":\"What main trends were observed after immunotherapy introduction?\",\"answer\":\"In advanced stages, survival at 18 months improved, while mean treatment costs increased in the most recent years.\"}]","Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia | PDF",1790028997,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1fea3140f72c1c6968e009c1116153a.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89b4f622483101be3ce7e35364100d4f.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5e43d4d46aed61ae0b24312086c322d.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7974a6a2d50a16bed410c19c2438aad.webp",980,1385]